BRYON EVANS: Open Payments
NPI 1942280011 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$123,446 in 345 payments from 27 companies in 2025. Trend: 2023 $22,064 · 2024 $46,437 · 2025 $123,446
Speaker / faculty: $60,331Honoraria: $40,700Travel & lodging: $10,324Food & beverage: $6,585Consulting: $5,500Education: $5
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 66 | $46,395 |
| Otsuka America Pharmaceutical, Inc. | 62 | $43,433 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 52 | $30,511 |
| Neurocrine BioSciences, Inc. | 22 | $639 |
| Alkermes, Inc. | 17 | $388 |
| Teva Pharmaceuticals USA, Inc. | 26 | $274 |
| Axsome Therapeutics, Inc. | 16 | $257 |
| Noven Therapeutics, LLC | 12 | $217 |
| Janssen Pharmaceuticals, Inc | 12 | $212 |
| Vanda Pharmaceuticals Inc. | 9 | $165 |
Products named: Qelbree, REXULTI, CAPLYTA, INGREZZA, ARISTADA, Auvelity, Xelstrym, FANAPT.
Industry payments across GA — which companies pay providers there.
